News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

8-K Vote – ImmunityBio, Inc. (0001326110) June 14 https://marketnewswire.live/index.php/2022/06/14/8-k-vote-immunitybio-inc-0001326110-june-14/?amp

Op-Ed: Course Correction, Paradigm Shifts And A Profound Truth "...However, the speech that resonated the most with me was the keynote address at dinner by Dr Patrick SoonShiong, the South African-born scientist, entrepreneur and billionaire. Dr Soon-Shiong’s journey is well-documented and has been a lifetime in the research and development of cancer-related Abraxane and then many other ventures including his current NantHealth and NantWorks that are focused on using his vast experience and resources to find a sustainable cure for cancer. He advocated the prioritization of healthcare in Africa, specifically building cancer centers, diagnostics and manufacturing in SA and perhaps over time, other parts of Africa. Of all the projects showcased, this one would unquestionably find financial backers including the African Development Bank that could easily underwrite the venture. It has to be seen whether the SA government steps up and accords approvals for expeditious implementation as this project could be a strategic pilot project that would inspire many others to follow. Another important message from Dr Soon-Shiong’s talk was his emphasis on self-reliance, particularly in the manufacturing of vaccines and medicines. Indigenization has been talked about for many years by almost all governments but the implementation ends up in vain as vested interests and unnecessary regulatory minefields prevent the setting up of sustainable projects in Africa." https://www.forbesafrica.com/opinion/op-ed/2022/06/07/course-correction-paradigm-shifts-and-a-profound-truth/

ImmunityBio (IBRX) Stock Price: $10 Target And Overweight Rating https://www.google.com/amp/s/pulse2.com/immunitybio-ibrx-stock-price-10-target-and-overweight-rating/amp/

ImmunityBio, Inc. @ImmunityBio We’re looking forward to participating in the #JefferiesHealthcare conference on Friday at 8:15 am ET. We will be discussing our therapeutic portfolio and clinical progress across a range of highly challenging cancer types including bladder, pancreatic, and lung.

ImmunityBio ASCO results show promise for therapies in bladder and pancreatic cancers Jun. 06, 2022 10:39 AM ETImmunityBio, Inc. (IBRX)By: Jonathan Block, SA News Editor https://seekingalpha.com/news/3845957-immunitybio-asco-results-show-promise-for-therapies-in-bladder-and-pancreatic-cancers

ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting JUNE 6, 2022 Data from trials underscore ImmunityBio’s vision of activating NK cells and T cells to advance care in difficult-to-treat cancers Bladder Cancer: 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed a complete response with a median duration of 26.6 months; cystectomy avoidance rate of 91% and 100% bladder cancer overall survival at 24 months with 0% immune-related serious adverse events (SAE) Advanced Metastatic Pancreatic Cancer: Nant Vaccine more than doubled median overall survival for patients versus historical overall survival with median overall survival in patients with third- to sixth-line pancreatic cancer at 6.2 months and treatment-related SAEs uncommon (6%) ImmunityBio is exhibiting at booth number 26135 https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-quilt-trial-results-bcg-unresponsive?field_nir_news_date_value[min]=

https://www.pharmaceutical-technology.com/comment/immunitybio-first-marketed-drug/

ImmunityBio, Inc. @ImmunityBio 1 Std. At #ASCO22, Dr. Tara Seery presents: Phase 2 clinical trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with 3rd-6th line advanced pancreatic cancer. https://bit.ly/3wYcNsk

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission https://seekingalpha.com/article/4516099-immunitybio-ready-to-shift-gears-after-long-awaited-bla-submission

ImmunityBio, Inc. @ImmunityBio 5 Min. Most cancer treatment plans weaken the immune system. At ImmunityBio, we work to create targeted immunotherapies designed to strengthen the immune system and outsmart the disease. This is why #CancerResearch is so imperative. https://immunitybio.com #NationalCancerResearchMonth

ImmunityBio, Inc. @ImmunityBio #ICYMI: ImmunityBio submitted a Biologics License Application to the US #FDA for N-803 for intravesical administration plus #BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (#NMIBC CIS).

Dr. Pat Soon-Shiong @DrPatSoonShiong 8 Std. Importance of that paper : “vaccines that do not provide sterilizing immunity (and therefore continue to permit transmission) will lead to a buildup of large standing populations of virus, greatly increasing the risk of immune escape.”

Dr. Pat Soon-Shiong @DrPatSoonShiong Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein

DUNKIRk: No easy path ahead for ImmunityBio ImmunityBio’s entrance into the northern Chautauqua County economy seemed promising earlier this year. Founded by billionaire Dr. Patrick Soon-Shiong, the company had high hopes after purchasing the former Athenex manufacturing facility. Recent numbers, however, are not as optimistic. As reported over this weekend, the early May filing with the SEC shows ImmunityBio losing $102,998,000 in the first three months of 2022 compared with a loss of $80,481,000 over the same time period in 2021. Overall, the company has lost $2.1 billion since it was founded, with losses coming from the costs of ongoing clinical trials and operations and research and development programs. “We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development,” the company reported in the filing. Former tenant of the site off Route 5 in Athenex, we must note, is suffering as well as its stock price continued to tumble. That being said, ImmunityBio has some major hurdles ahead of it. Some of their treatments being studied in clinical trials involve cancers and COVID-19 vaccine. As the world of health care continues to evolve, there’s been a fair share of uncertainty. As a new partner to Dunkirk, ImmunityBio is clearly in that mix. https://www.observertoday.com/opinion/the-observers-view/2022/05/dunkirk-no-easy-path-ahead-for-immunitybio/

ImmunityBio, Inc. @ImmunityBio 3 Std. See these ImmunityBio papers for details on our COVID-19 vaccine research: https://www.biorxiv.org/content/10.1101/2021.11.29.470440v2

ImmunityBio, Inc. @ImmunityBio 3 Std. Timely paper by Vall d’Hebron researchers, et al., suggests mRNA vaccines elicit only very modest memory T cell protection against SARS-CoV-2 in the lung. This has been our hypothesis since the onset of the pandemic. @vallhebron